Daiichi Sankyo Company, Limited (TYO:4568)
Japan · Delayed Price · Currency is JPY 2,794.00
-60.50 (-2.12%)
Sep 4, 2026, 3:30 PM JST
[Name] Revenue
Daiichi Sankyo Company had revenue of 574.74B JPY in the quarter ending June 30, 2026, with 21.10% growth. This brings the company's revenue in the last twelve months to 2.22T, up 15.51% year-over-year. In the fiscal year ending March 31, 2026, Daiichi Sankyo Company had annual revenue of 2.12T with 12.55% growth.
Revenue (ttm)
2.22T
Revenue Growth
+15.51%
P/S Ratio
2.29
Revenue / Employee
110.22M
Employees
20,171
Market Cap
5.09T
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 2.12T | 236.79B | 12.55% |
| Mar 31, 2025 | 1.89T | 284.57B | 17.77% |
| Mar 31, 2024 | 1.60T | 323.21B | 25.28% |
| Mar 31, 2023 | 1.28T | 233.59B | 22.36% |
| Mar 31, 2022 | 1.04T | 82.38B | 8.56% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Takeda Pharmaceutical Company | 4.62T |
| Otsuka Holdings | 2.62T |
| Astellas Pharma | 2.27T |
| Chugai Pharmaceutical | 1.34T |
| Terumo | 1.18T |
| Olympus | 1.04T |
| HOYA Corporation | 983.64B |
| Eisai | 857.06B |
Daiichi Sankyo Company News
- 7 days ago - New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk - Business Wire
- 9 days ago - TROPION-Urothelial04 Phase 3 Trial of Datroway® Initiated as Adjuvant Therapy in Patients with High-Risk Muscle Invasive Urothelial Cancer - Business Wire
- 11 days ago - Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization - Business Wire
- 11 days ago - Daiichi Sankyo Appoints Ken Keller as Chief Commercialization Officer to Lead New Commercialization Unit to Accelerate Growth of Innovative Portfolio - Business Wire
- 18 days ago - Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial - Business Wire
- 25 days ago - Innovent Biologics and Daiichi Sankyo Enter Exclusive Agreement for VANFLYTA® Commercialization in China - PRNewsWire
- 5 weeks ago - Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results - Business Wire
- 5 weeks ago - Daiichi Sankyo Company Earnings Call Transcript: Q1 2027 - Transcripts